- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05928624
A Pilot Trial to Test the Feasibility of Utilizing Home Blood Pressure Monitoring to Optimize the Administration of Midodrine Among Decompensated Cirrhosis Patients (WATCH)
November 27, 2023 updated by: University of California, San Francisco
Wireless Automated Tracking in Cirrhosis Patients at Home (WATCH) Trial: A Randomized Single Blind Trial Testing the Use of Home Monitoring Among Decompensated Cirrhosis Patients
This is a randomized single-blind feasibility trial to test the utilization of home blood pressure devices to improve the clinical management of decompensated cirrhosis patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a feasibility trial to determine the feasibility of using home monitoring devices (e.g.
blood pressure cuffs) to improve outcomes for cirrhosis patients.
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Giuseppe Cullaro, MD, MAS
- Phone Number: 415 476 3143
- Email: giuseppe.cullaro@ucsf.edu
Study Contact Backup
- Name: Hannah Chao
- Email: hannah.chao@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- Recruiting
- University of California San Francisco
-
Contact:
- Giuseppe Cullaro, MD, MAS
- Phone Number: 415-476-3143
- Email: giuseppe.cullaro@ucsf.edu
-
Contact:
- Hannah Chao
- Phone Number: 415 476 3143
- Email: hannah.chao@ucsf.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients will need to have decompensated cirrhosis defined as a Child Pugh Score ≥ 7
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Standard of Care
This arm will receive a home blood pressure monitor and scale; however, these data will not be shared with their treating provider in real-time.
|
Standard of Care
|
Experimental: Home Blood Pressure and Scale Monitoring to Inform Clinical Decisions
This arm will receive a home blood pressure monitor and scale.
These data will be reviewed weekly and these data will be shared with the treating provider to inform clinical decisions.
|
The intervention will be whether the data generated from home monitoring devices are shared with the clinical providers.
The investigators are not testing the efficacy of these approved devices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean Arterial Pressure
Time Frame: Baseline and 24 Weeks
|
The investigators will compare the change in mean arterial pressure before and after utilization of the data generated from the home monitoring.
|
Baseline and 24 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Ascites Burden
Time Frame: Baseline and 24 Weeks
|
The investigators will compare the change in ascites burden, defined as the total volume of ascites removed during the study period, before and after utilization of the data generated from the home monitoring.
|
Baseline and 24 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Giuseppe Cullaro, MD, MAS, University of California, San Francisco
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 22, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
June 23, 2023
First Submitted That Met QC Criteria
June 30, 2023
First Posted (Actual)
July 3, 2023
Study Record Updates
Last Update Posted (Actual)
November 29, 2023
Last Update Submitted That Met QC Criteria
November 27, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-36046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Hypertension
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingIntrahepatic Non Cirrhotic Portal HypertensionFrance
-
Centro Hospitalar De São João, E.P.E.CompletedClinically Significant Portal HypertensionPortugal
-
University Hospital, ToursCompletedCirrhotic Portal HypertensionFrance
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPortal Hypertension | Clinically Significant Portal HypertensionUnited States
-
University Hospital, GhentCompletedEvaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.Liver Transplant With Clinically Significant Portal HypertensionBelgium
-
Universidade Federal do Rio de JaneiroNot yet recruitingPortal Hypertension | Idiopathic Non-Cirrhotic Portal Hypertension | Non-Cirrhotic Portal Hypertension | Vascular Disorder of Liver | Non-Cirrhotic Portal Fibrosis | Regenerative Nodular Hyperplasia | Incomplete Septal Cirrhosis | Obliterative Portal Venopathy | Hepatoportal Sclerosis | Idiopathic Portal...Brazil
-
Ain Shams UniversityCompleted
-
Assiut UniversityUnknownPredicting Liver Cell Failure & Portal Hypertension in LCEgypt
-
University Hospital, BonnCompleted
-
Tanta UniversityCompleted
Clinical Trials on Standard of Care
-
brett rasmussenCompleted
-
Johns Hopkins UniversityRecruitingCompartment Syndrome of Leg | Extracorporeal Membrane Oxygenation Complication | Limb Ischemia, Critical | Limb IschemiaUnited States
-
Indonesia UniversityCompletedCovid19 | AcupunctureIndonesia
-
Aventusoft, LLC.National Heart, Lung, and Blood Institute (NHLBI); Cleveland Clinic FloridaRecruitingHeart Failure (HF)United States
-
Vascular Biogenics Ltd. operating as VBL TherapeuticsCompletedSevere COVID-19Israel
-
Ruijin HospitalRecruitingCOVID-19 PneumoniaChina
-
Institut Claudius RegaudCompletedMETASTATIC CANCERFrance
-
Ziv HospitalNot yet recruiting
-
Hofseth Biocare ASAKGK Science Inc.CompletedCovid-19 | COVIDCanada, Brazil, Hungary, Mexico, Serbia
-
City University of New York, School of Public HealthNew York State Psychiatric Institute; University of KwaZulu; International Initiative... and other collaboratorsCompleted